• Explore /
  • Poster
  • / Identification of a gene expression signature predictive of clinical benefit in patients with advanced mucosal melanoma (MCM) treated with immune checkpoint blockade.

Identification of a gene expression signature predictive of clinical benefit in patients with advanced mucosal melanoma (MCM) treated with immune checkpoint blockade.

Abstract Poster

Authors

null

Suthee Rapisuwon

Georgetown University, Lombardi Comprehensive Cancer Center, Washington, DC

Suthee Rapisuwon , Alexander Noor Shoushtari , Lee S. Gottesdiener , Douglas Buckner Johnson , Daniel Ying Wang , Garrett Thomas Graham , David Goerlitz , Deborah Berry , Michael B. Atkins

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Melanoma/Skin Cancers

Track

Melanoma/Skin Cancers

Sub Track

Advanced/Metastatic Disease

Citation

J Clin Oncol 37, 2019 (suppl; abstr 9546)

DOI

10.1200/JCO.2019.37.15_suppl.9546

Abstract #

9546

Poster Bd #

117

Abstract Disclosures

Similar Posters

Poster

2023 ASCO Annual Meeting

Phase II clinical trial of camrelizumab combined with famitinib for advanced acral and mucosal melanoma.

Phase II clinical trial of camrelizumab combined with famitinib for advanced acral and mucosal melanoma.

First Author: Lili Mao

First Author: Milad Ibrahim

First Author: Charlee Nardin

First Author: Daniel Ying Wang